{"id":57736,"date":"2025-07-11T16:24:54","date_gmt":"2025-07-11T10:54:54","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=57736"},"modified":"2025-11-06T23:23:29","modified_gmt":"2025-11-06T17:53:29","slug":"glenmark-pharmas-mega-deal-with-abbvie-5-things-investors-should-track","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/glenmark-pharmas-mega-deal-with-abbvie-5-things-investors-should-track\/","title":{"rendered":"Glenmark Pharma’s Mega Deal with AbbVie: 5 Things Investors Should Track"},"content":{"rendered":"
<\/div>\n

<\/p>\n\n\n\n

It\u2019s a new era for Glenmark Pharma<\/a>!<\/p>\n\n\n\n

Shares of the pharma company surged over 14% today following the company\u2019s announcement that its subsidiary Ichnos Glenmark Innovation (IGI) has signed an exclusive licensing agreement with AbbVie.<\/p>\n\n\n\n

This licensing deal is for the subsidiary\u2019s lead investigational asset – ISB 2001 – for use in oncology and autoimmune diseases.<\/p>\n\n\n\n

Glenmark Share Price Performance<\/strong><\/p>\n\n\n\n\n\n

Licensing Deal Details<\/h1>\n\n\n\n

Under the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB-2001 across key developed markets, including North America, Europe, Japan, and Greater China.<\/p>\n\n\n\n

Meanwhile, Glenmark will retain the rights to develop, manufacture, and sell in emerging markets.<\/p>\n\n\n\n

Glenmark\u2019s subsidiary will receive an upfront payment of $700 million from AbbVie. Additionally, Glenmark is also eligible to earn up to $1.2 billion through achievement-based development, regulatory, and commercial milestone payments. IGI will also receive royalties on sales generated by AbbVie.<\/p>\n\n\n\n

Snapshot of Licensed Deal<\/strong><\/p>\n\n\n\n

Aspect<\/strong><\/td>Details<\/strong><\/td><\/tr>
Drug<\/td>ISB-2001<\/td><\/tr>
Developed Markets<\/td>AbbVie gets exclusive rights (North America, Europe, Japan, Greater China)<\/td><\/tr>
Emerging Markets<\/td>Glenmark retains rights<\/td><\/tr>
Upfront Payment<\/td>$700 million to Glenmark\u2019s subsidiary<\/td><\/tr>
Milestone Payments<\/td>Up to $1.2 billion (development, regulatory, and commercial milestones)<\/td><\/tr>
Royalties<\/td>Glenmark to receive royalties on AbbVie\u2019s sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The ISB-2001 is an experimental cancer drug<\/a> designed to treat multiple myeloma (a type of blood cancer) by helping the immune system attack cancer cells more effectively. <\/p>\n\n\n\n

It targets two cancer markers instead of one, making it harder for the cancer to resist treatment \u2014 and early results show it may work better than current options.<\/p>\n\n\n\n

Note that this deal ranks as the fourth-largest deal in the pharma sector based on the size of the upfront payment.<\/p>\n\n\n\n

Licensed Deals with Upfront Payments<\/strong><\/p>\n\n\n\n\n\n

Source: Motilal Oswal<\/p>\n\n\n\n

About Glenmark Pharma<\/h1>\n\n\n\n

Glenmark Pharma is engaged in developing pharmaceutical product formulation and active pharmaceutical ingredients in regulated and semi-regulated markets. The company has several molecules in the areas of oncology<\/a>, respiratory, and dermatology.<\/p>\n\n\n\n

Its branded generics business has a significant presence in markets across emerging economies, including India.<\/p>\n\n\n\n

Glenmark Pharma Revenue Contribution (FY25 Revenue Rs 13,322 Cr.)<\/strong><\/p>\n\n\n\n\n\n

Source: Investor Presentation<\/p>\n\n\n\n

Financial Snapshot<\/h1>\n\n\n\n

For FY25, Glenmark posted a 12.8% jump in its consolidated revenues while it also turned to profit this year, following a loss in FY24 owing to declining sales in the US.<\/p>\n\n\n\n

Financial Highlights<\/strong><\/p>\n\n\n\n

Particulars<\/strong><\/td>FY24<\/strong><\/td>FY25<\/strong><\/td>Growth (%)<\/strong><\/td><\/tr>
Revenue<\/td>11,813<\/td>13,322<\/td>13%<\/td><\/tr>
EBITDA<\/td>1,195<\/td>2,351<\/td>97%<\/td><\/tr>
EBITDA Margin (%)<\/td>10%<\/td>18%<\/td>–<\/td><\/tr>
Net Profit<\/td>-1,434<\/td>1,047<\/td>–<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Source: Investor Presentation<\/p>\n\n\n\n

Outlook<\/h1>\n\n\n\n

The recent deal with AbbVie is a strong boost for Glenmark. It shows confidence in their BEAT protein platform, highlights the potential of ISB-2001 in treating difficult cases of multiple myeloma, and confirms its commercial promise if trials go well. <\/p>\n\n\n\n

AbbVie\u2019s involvement adds further credibility, given its success in launching cancer drugs like Imbruvica and Venclexta, both of which have changed how blood cancers are treated and generated billions in revenue.<\/p>\n\n\n\n

Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis – Research & Ranking. We will not be liable for any losses that may occur. Investments<\/a> in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI<\/a>, membership of BASL & the certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.<\/p>\n","protected":false},"excerpt":{"rendered":"

It\u2019s a new era for Glenmark Pharma! Shares of the pharma company surged over 14% today following the company\u2019s announcement […]<\/p>\n","protected":false},"author":22,"featured_media":57738,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[948],"tags":[],"class_list":["post-57736","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-market-news"],"_links":{"self":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/57736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/comments?post=57736"}],"version-history":[{"count":5,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/57736\/revisions"}],"predecessor-version":[{"id":59707,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/57736\/revisions\/59707"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media\/57738"}],"wp:attachment":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media?parent=57736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/categories?post=57736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/tags?post=57736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}